Every month someone asks the same question: which GLP-1 drug produces the most weight loss?

An updated systematic review published September 1, 2026 gives the most comprehensive answer yet — pooling 38 randomized controlled trials across 25,816 adults without diabetes.

Here's what the data actually shows, what the caveats are, and why the numbers matter less than most people think.

The Placebo-Adjusted Weight Loss Hierarchy

The review calculated placebo-adjusted weight loss — meaning the drug's effect above and beyond what the placebo group lost — across marketed and investigational agents.

Marketed drugs (placebo-adjusted weight loss):

Drug	Mechanism	Route	Placebo-adjusted weight loss
Tirzepatide	GLP-1 + GIP	Injectable	~19.0%
Semaglutide (injectable)	GLP-1	Injectable	~14.8%
Semaglutide (oral)	GLP-1	Oral	~14.3%
Orforglipron (Foundayo)	GLP-1	Oral	~12.4%
Liraglutide (Saxenda)	GLP-1	Injectable	~5.8%

Investigational agents (not yet approved) reached greater placebo-adjusted reductions in the same review — retatrutide ~22.1% and amycretin (now zenagamtide) ~23.9%. Separately, eloralintide, a selective amylin receptor agonist not included in this review, reached ~20% at the 9 mg dose in its 48-week Phase 2 trial against ~0.4% on placebo.

Source: Moiz A, et al. "Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes: An Updated Systematic Review." Annals of Internal Medicine, September 1, 2026. 38 randomized trials, 25,816 adults. DOI 10.7326/ANNALS-25-05519.

What These Numbers Mean — and Don't Mean

Before anyone uses this as a simple ranking to decide which drug to ask their doctor about, several important caveats:

Cross-trial comparisons are directional, not head-to-head precise. These trials differ in populations (average BMI, age, comorbidities), durations (24 weeks vs 72+ weeks), dosing protocols, and placebo dropout rates. Pooling them produces a defensible hierarchy — but it's not the same as a single randomized trial that compared all these drugs head-to-head in the same population at the same time.

Population composition varies. The review specifically examined adults without diabetes. This is a different population than the T2D trials that produced some of the highest weight loss numbers for drugs like tirzepatide. Diabetes complicates weight loss outcomes.

Duration matters. A 24-week result and a 72-week result are not the same thing. Longer trials tend to show continued loss followed by plateau. The hierarchy above reflects mixed durations.

Individual response varies enormously. Population averages obscure huge individual variation. Some people lose 30%+ on semaglutide. Some lose 5%. The average doesn't predict your result.

Why the Oral Drugs Are a Bigger Story Than They Look

The most strategically important finding in this hierarchy isn't tirzepatide at 19% — we've known that for years.

It's that oral semaglutide (~14.3%) is tracking nearly identically to injectable semaglutide (~14.8%).

And orforglipron (Foundayo), the first FDA-approved oral GLP-1 with no food or water restrictions, is at ~12.4%.

The efficacy gap between injectable and oral has nearly closed. And oral administration removes the primary barrier to access for a large segment of the population who are unwilling or unable to self-inject.

This is why every major pharmaceutical company is racing to the oral formulation finish line — VCT220 (Phase 2, China), aleniglipron (Phase 3), TERN-601 (Phase 2), and others are all in active development.

The injectable era is not over. But the oral era has started.

What Comes After This Generation

The hierarchy above reflects the current approved and late-stage investigational landscape. The next generation is already in Phase 2 and 3, and the numbers are substantially larger:

Retatrutide (triple agonist: GLP-1 + GIP + Glucagon): ~28.3% at 80 weeks in TRIUMPH-1 (non-diabetes population). BLA filing planned Q1 2027.

Eloralintide (amylin receptor agonist): ~20.1% at 48 weeks in Phase 2 as a standalone, without touching GLP-1, GIP, or glucagon receptors. Phase 3 underway.

CagriSema (GLP-1 + amylin combination): ~22.7% at 68 weeks in REDEFINE Phase 3 (Novo Nordisk). NDA filed.

Zenagamtide (GLP-1/amylin co-agonist, formerly amycretin): Phase 2 data showed ~22% at 36 weeks. Phase 3 planned.

The obesity drug pipeline has never been more active. The ~19% ceiling from tirzepatide — impressive as it is — appears to be a floor for the next wave.

The Part Nobody Plans For

All of these numbers are from trials where people stayed on the drug.

What happens when they stop?

An August 2026 narrative review reports real-world discontinuation at 85% within two years. A separate 2026 meta-regression found that about 60% of the weight lost is regained one year after stopping, with regain projected to plateau at roughly 75% of the loss and a regain half-life of about 23 weeks.

The regain is fat-preferential — lean mass losses during treatment don't return the same way the fat does.

This means someone who achieved 19% weight loss on tirzepatide and then discontinued could, within a year or two, be most of the way back to their starting scale weight with worse body composition.

The drug hierarchy above answers "which produces the most weight loss during treatment." It doesn't answer the equally important question: what's the plan for maintaining results?

That's where tracking — body composition, not just scale weight, through the entire journey including any gaps or transitions — matters as much as which drug you're on.

How to Read Your Own Numbers

Most people running any of these protocols track one number: scale weight.

The systematic review above measured placebo-adjusted weight loss. But the clinical question for any individual is more nuanced than that number:

How much of the weight lost is fat vs. muscle?
Is visceral fat — the metabolically dangerous fat — actually declining?
Are cardiometabolic markers improving (blood pressure, lipids, glucose, inflammatory markers)?
How is energy, mood, and recovery tracking alongside the weight?

All of these are measurable. None of them appear on a bathroom scale.

PeptidesGPT tracks body composition (weight, skeletal muscle mass, body fat percentage), daily check-ins (energy, mood, sleep, recovery), bloodwork trends, and protocol version by version — so your data tells the complete story, not just the one number.

→ Start tracking at PeptidesGPT.com

Sources:

Moiz A, et al. "Efficacy and Safety of GLP-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes: An Updated Systematic Review." Ann Intern Med. 2026 Sep 1. PMID 42673585. DOI 10.7326/ANNALS-25-05519.
Lilly TRIUMPH-1 (retatrutide): NCT05929066. Topline release May 21, 2026.
Billings LK, et al. "Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2 … trial." Lancet. 2025;406(10520):2631–2643. PMID 41207310. DOI 10.1016/S0140-6736(25)02155-5.
CagriSema REDEFINE 1: Novo Nordisk, ADA 2026.
Zeigler Z, et al. "Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review." Healthcare (Basel). 2026;14(15). PMID 42588312. DOI 10.3390/healthcare14152345.
Budini B, et al. "Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression." EClinicalMedicine. 2026;93:103796. PMID 41938838. DOI 10.1016/j.eclinm.2026.103796.

PeptidesGPT is an educational platform. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication or protocol.